Newest
-
SeerQ's first participation in the Hong Kong Brands and Products Expo Shopping Festival concluded successfully
-
SeerQ Wins AI+Innovation Enterprise Excellence Award: AI-Empowered Eastern Wisdom Receives High Industry Recognition
-
AI, Sustainability, and the Future of Fashion: Emerging Researcher Kang Zhemiao Proposes a New Industrial Paradigm
-
Nato sends in military forces after Russia unleashes fresh round of air strikes
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
2024-11-01
I-Mab Biopharma
HaiPress

ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
